Program
RBD1119
A development code.
Its studies are mostly in Coronary Artery Disease, led by Suzhou Ribo Life Science.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Ribo Life Science | 22 open or running | phase 2since Oct 13, 2026 | Jun 13, 2025 | Sep 30, 2027phase 2 · NCT07884136 |
Also a collaborator on its studies: Fortrea.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 13, 2025First study: phase 1 study in Healthy VolunteersFirst studyNCT07042594 · 32 enrolled · Australia
- Oct 13, 2026Phase 2 study in Stable Coronary Artery DiseasePhase 2 reachedNCT07884136 · 200 planned · Poland, Sweden
Ahead
- Sep 30, 2027Primary completion: phase 2 study in Stable Coronary Artery DiseaseNCT07884136
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07884136Stable Coronary Artery Disease · Poland, Sweden | 2 | Not yet recruiting | Sep 30, 2027 | 200 |
| NCT07042594Healthy Volunteers · Australia | 1 | Active, not recruiting | Aug 5, 2026 | 32 |
How it is read
Names in the registry
- “RBD1119”, 2 entries
Codes read as this program: RBD1119.
Conditions, from the studies’ own filings
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.